Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Rising demands and advancements in eye care drive growth
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Subscribe To Our Newsletter & Stay Updated
